Krystal Biotech Analysts Increase Their Forecasts Following Q4 Results - Krystal Biotech (NASDAQ:KRYS)
Krystal Biotech, Inc. (NASDAQ: KRYS) reported better-than-expected financial results for its fourth quarter on Monday.
Source: benzinga.com
Krishs Krishnan News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Krishs Krishnan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Krishs Krishnan Today - Breaking & Trending Today
Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights
• VYJUVEK™ approved in the U.S. as the first and only topical redosable gene therapy for the treatment of dystrophic epidermolysis bullosa • 121 Patient Start Forms in the first six weeks of...
Source: marketscreener.com
FDA Approval, Private Placement Funding Buoy Biotech Firm
FDA Approval, Private Placement Funding Buoy Biotech Firm
Source: investorideas.com
Krystal Biotech to Present at Upcoming Investor Conferences
05.06.2023 - PITTSBURGH, June 05, 2023 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company ...
Source: wallstreet-online.de
Krystal Biotech Announces $160 Million Private Placement Equity Financing
22.05.2023 - PITTSBURGH, May 22, 2023 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced that it has ... Seite 1
Source: wallstreet-online.de